Gestational diabetes & diabetes in pregnancy
Predicting the Risk of Adverse Neonatal Outcomes in Women With Insulin-Treated Diabetes: Is It Time for a Pregnancy-Specific Glycemic Risk Index?
Authors' conclusion
Pregnant women with insulin-treated diabetes reporting adverse neonatal outcomes spent more time in hyperglycemia, particularly in extreme hyperglycemia. Therefore, the level of hyperglycemia should always be assessed during pregnancy. The pGRI, emphasizing extreme hyperglycemia, may be a novel comprehensive tool for assessing the risk of adverse neonatal outcomes.
Study context
- Population
- Pregnant women with insulin-treated diabetes using Continuous Glucose Monitoring (CGM), University Hospital of Pisa, September 2021–March 2024
- Participants
- 45 women
- Exposure
- Women with vs without adverse neonatal outcomes
- Adverse outcomesn = 25
- Outcome
- Association between pregnancy-specific Glycemia Risk Index (GRI) (pGRI) and risk of at least one adverse neonatal outcome (preterm delivery, macrosomia, LGA, SGA, neonatal hypoglycemia, neonatal jaundice, neonatal ICU admission)
- Follow-up
- Each trimester
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
P = 0.013
- P for logistic regression
- P = 0.024
Observational data: associations, not effects.
Further findings
Total TAR · third trimester · higher with adverse outcomes
P = 0.018
TIR · third trimester · lower with adverse outcomes
P = 0.007
- TAR2 (>180 mg/dL) · third trimester · difference notable in TAR2
- P = 0.004
TAR1 (140-180 mg/dL) · third trimester
- TAR1 was comparable between the 2 groups
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →